Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Incyte Corporation - Common Stock (NQ:INCY)

101.57 +8.09 (+8.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stay informed with the top movers within the S&P500 index on Monday.
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday. 
Via Chartmill
Kenvue, IDEXX Laboratories, Freshpet And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below. 
Via Chartmill
Earnings Scheduled For October 28, 2025
 
Via Benzinga
Exploring Incyte's Earnings Expectations
 
Via Benzinga
Exploring the top movers within the S&P500 index during today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of... 
Via StockStory
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms
Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook. 
Via Benzinga
Topics Intellectual Property
These S&P500 stocks have an unusual volume in today's session
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. 
Via Chartmill
Why Incyte (INCY) Stock Is Trading Lower Today
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results. 
Via StockStory
Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday?
Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech earnings. 
Via Benzinga
Topics Economy
Incyte (INCY) Q3 2025 Earnings Call Transcript
Incyte (INCY) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views
The company delivered significantly better-than-expected third-quarter sales and earnings, but shares took a premarket hit. 
Via Investor's Business Daily
Topics Government
Incyte Corp (NASDAQ:INCY) Reports Strong Q3 2025 Earnings, Beating Estimates
Incyte (INCY) Q3 2025 earnings beat expectations with $1.37B revenue and $2.26 EPS. Driven by Jakafi and Opzelura growth, the company also raised its full-year 2025 guidance. 
Via Chartmill
Topics Earnings
Incyte (NASDAQ:INCY) Reports Strong Q3
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 20% year on year to $1.37 billion. Its non-GAAP profit of $2.26 per share... 
Via StockStory
Topics Artificial Intelligence
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Incyte
Via Business Wire
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
From Incyte and Enable Injections
Via Business Wire
What To Expect From Incyte’s (INCY) Q3 Earnings
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings this Tuesday morning. Here’s what you need to know. 
Via StockStory
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
From Incyte
Via Business Wire
Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth. 
Via Benzinga
INCYTE CORP (NASDAQ:INCY) Presents a Value Investing Opportunity with Strong Fundamentals
INCYTE CORP (INCY) appears undervalued with strong profitability and a healthy balance sheet. Its low P/E and high ROE suggest a potential value investing opportunity. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Monday. Discover the gap up and gap down stocks in the S&P500 index. 
Via Chartmill
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
From Incyte
Via Business Wire
Incyte (INCY) Stock Is Up, What You Need To Know
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 1.5% in the afternoon session after the company announced Health Canada's approval of its Opzelura cream for treating atopic... 
Via StockStory
Topics Artificial Intelligence
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000
Via The Motley Fool
Topics Regulatory Compliance
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
From Incyte
Via Business Wire
JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance
JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the... 
Via MarketMinute
Topics Economy Intellectual Property
What 14 Analyst Ratings Have To Say About Incyte
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.